A structured benefit-risk assessment to evaluate a combination of olanzapine and samidorphan for the treatment of schizophrenia and bipolar i disorder
BIPOLAR DISORDERS(2022)
摘要
Alkermes, Inc.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要